Nambi, Vijay

Obesity and subtypes of incident cardiovascular disease

Ndumele, C. E., Matsushita, K., Lazo, M., Bello, N., Blumenthal, R. S., Gerstenblith, G., Nambi, V., Ballantyne, C. M., Solomon, S. D., Selvin, E., et al. (2016) · Journal of the American Heart Association

Cardiovascular Function and Risk FactorsDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 259

Meta-analysis of genome-wide association studies from the CHARGE consortium identifies common variants associated with carotid intima media thickness and plaque

the CARDIoGRAM Consortium, Bis, J. C., Kavousi, M., Franceschini, N., Isaacs, A., Abecasis, G. R., Schminke, U., Post, W. S., Smith, A. V., Cupples, L. A., et al. (2011) · Nature Genetics

Genetic Associations and EpidemiologyCardiovascular Health and Disease Prevention

Cited by 212

2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines

Writing Committee Members, Blumenthal, R. S., Morris, P. B., Gaudino, M., Johnson, H. M., Anderson, T. S., Bittner, V. A., Blankstein, R., Brewer, L. C., Cho, L., et al. (2026) · Circulation

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 122

Prediction of individualized lifetime benefit from cholesterol lowering, blood pressure lowering, antithrombotic therapy, and smoking cessation in apparently healthy people

Jaspers, N. E. M., Blaha, M. J., Matsushita, K., van der Schouw, Y. T., Wareham, N. J., Khaw, K.-T., Geisel, M. H., Lehmann, N., Erbel, R., Jöckel, K.-H., et al. (2020) · European Heart Journal

Health Promotion and Cardiovascular PreventionLipoproteins and Cardiovascular Health

Cited by 120

Adoption of the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guideline in Cardiology Practices Nationwide

Pokharel, Y., Tang, F., Jones, P. G., Nambi, V., Bittner, V. A., Hira, R. S., Nasir, K., Chan, P. S., Maddox, T. M., Oetgen, W. J., et al. (2017) · JAMA Cardiology

Lipoproteins and Cardiovascular HealthClinical practice guidelines implementation

Cited by 107

High-sensitivity cardiac troponin T and the risk of incident atrial fibrillation: The Atherosclerosis Risk in Communities (ARIC) study

Filion, K. B., Agarwal, S. K., Ballantyne, C. M., Eberg, M., Hoogeveen, R. C., Huxley, R. R., Loehr, L. R., Nambi, V., Soliman, E. Z., & Alonso, A. (2015) · American Heart Journal

Atrial Fibrillation Management and OutcomesAcute Myocardial Infarction Research

Cited by 73

A genetic risk score based on direct associations with coronary heart disease improves coronary heart disease risk prediction in the Atherosclerosis Risk in Communities (ARIC), but not in the Rotterdam and Framingham Offspring, Studies

Brautbar, A., Pompeii, L. A., Dehghan, A., Ngwa, J. S., Nambi, V., Virani, S. S., Rivadeneira, F., Uitterlinden, A. G., Hofman, A., Witteman, J. C. M., et al. (2012) · Atherosclerosis

Genetic Associations and EpidemiologyNutrition, Genetics, and Disease

Cited by 71

Six-Year Changes in Physical Activity and the Risk of Incident Heart Failure: ARIC Study

Florido, R., Kwak, L., Lazo, M., Nambi, V., Ahmed, H. M., Hegde, S. M., Gerstenblith, G., Blumenthal, R. S., Ballantyne, C. M., Selvin, E., et al. (2018) · Circulation

Physical Activity and HealthCardiovascular and exercise physiology

Cited by 56

Association Between Lipid Testing and Statin Adherence in the Veterans Affairs Health System

Jia, X., Al Rifai, M., Ramsey, D. J., Ahmed, S. T., Akeroyd, J. M., Nambi, V., Ballantyne, C. M., Petersen, L. A., Stone, N. J., & Virani, S. S. (2019) · The American Journal of Medicine

Medication Adherence and ComplianceLipoproteins and Cardiovascular Health

Cited by 41

The role of antisense oligonucleotide therapy in patients with familial hypercholesterolemia: risks, benefits, and management recommendations

Agarwala, A., Jones, P., & Nambi, V. (2015) · Current Atherosclerosis Reports

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 31

Association between omega-3 fatty acid treatment and atrial fibrillation in cardiovascular outcome trials: a systematic review and meta-analysis

Jia, X., Gao, F., Pickett, J. K., Al Rifai, M., Birnbaum, Y., Nambi, V., Virani, S. S., & Ballantyne, C. M. (2021) · Cardiovascular Drugs and Therapy

Fatty Acid Research and HealthAtrial Fibrillation Management and Outcomes

Cited by 27

Inclisiran as a siRNA Inhibitor of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9); Past, Present, and Future

Mansoor, T., Rao, B. H., Gupta, K., Parikh, S. S., Abramov, D., Mehta, A., Al Rifai, M., Virani, S. S., Nambi, V., Minhas, A. M. K., et al. (2025) · American Journal of Cardiovascular Drugs

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 12

Has the ‘strength’ of fish oil therapy been ‘reduced’? Reconciling the results of REDUCE-IT and STRENGTH

Virani, S. S., Nambi, V., & Ballantyne, C. M. (2021) · European Heart Journal - Cardiovascular Pharmacotherapy

Fatty Acid Research and HealthLipoproteins and Cardiovascular Health

Cited by 10

Predicted Risk, Preclinical Heart Failure Measures, and Incident Heart Failure

Grant, J. K., Zhang, S., Khan, S. S., Ozkan, B., Blumer, V., Nambi, V., Echouffo-Tcheugui, J. B., Pandey, A., Blumenthal, R. S., Ballantyne, C. M., et al. (2025) · JACC: Heart Failure

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 8